메뉴 건너뛰기
Clinical Drug Investigation
Volumn 28, Issue 7, 2008, Pages 461-462
The importance of cost inputs and sensitivity analyses in a cost-effectiveness analysis
Author keywords

Cost effectiveness; Cyclophosphamide, therapeutic use; Diffuse large B cell lymphoma; Doxorubicin, therapeutic use; Prednisone, therapeutic use; Rituximab, therapeutic use; Vincristine, therapeutic use
Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;
EID: 44949171544     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828070-00007     Document Type: Letter
Times cited : (1)
References (7)
  • 1
    • 37249071776 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma
    • Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Invest 2008; 28 (1): 55-65
    • (2008) Clin Drug Invest , vol.28 , Issue.1 , pp. 55-65
    • Ferrara, F.1    Ravasio, R.2
  • 2
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7 (5): 379-91
    • (2006) Lancet Oncol , vol.7 , Issue.5 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 3
    • 0036153857 scopus 로고    scopus 로고
    • Pitfalls associated with commonly used methods for pharmacoeconomic analyses
    • Klepser D. Pitfalls associated with commonly used methods for pharmacoeconomic analyses. Pharmacotherapy 2002; 22 (22 Suppl.): 35s-8s
    • (2002) Pharmacotherapy , vol.22 , Issue.22 SUPPL.
    • Klepser, D.1
  • 4
    • 33244458272 scopus 로고    scopus 로고
    • Managing oncology costs
    • Reeder C, Gordon D. Managing oncology costs. Am J Manag Care 2006; Suppl. 12: 3-16
    • (2006) Am J Manag Care , vol.12 , Issue.SUPPL. , pp. 3-16
    • Reeder, C.1    Gordon, D.2
  • 5
    • 0034750311 scopus 로고    scopus 로고
    • Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients
    • Oct;
    • Calhoun E, Chang CH, Welshman E, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001 Oct; 6 (5): 441-5
    • (2001) Oncologist , vol.6 , Issue.5 , pp. 441-445
    • Calhoun, E.1    Chang, C.H.2    Welshman, E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.